AZ Combo Extends Lung Cancer Survival

AstraZeneca's VOLGA Phase III trial showed that perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced the risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer patients. The combination therapy demonstrated statistically significant improvements in event-free survival and overall survival compared to the standard of care. According to AstraZeneca, more than three quarters of patients were still alive two years after treatment.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced mortality risk by 58% in a lung cancer trial. Imdelltra's US list price is around $300,000 per cycle. Analysts project annual revenues exceeding $2.5B by 2030. The drug is approved for extensive-stage small cell lung cancer, with 80% of trial patients alive at one year.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, showed a 58% reduction in death risk in a lung cancer trial. Median survival was 21.1 months vs. 12.7 months for Imfinzi alone. Amgen's chief medical officer called the results unprecedented. The drug's list price is $30,000 per cycle, with estimated sales over $2.5B by 2030. The trial involved 563 patients and was presented at a medical conference.

AstraZeneca's IMFINZI with neoadjuvant EV showed significant improvements in event-free and overall survival in muscle-invasive bladder cancer patients. The combination reduced the risk of disease progression by 49% and death by 42% compared to standard care. The FDA granted Priority Review for this treatment in September 2026. The VOLGA Phase III trial involved 695 patients across 182 centers in 25 countries.

Amgen reported Phase 3 trial results showing IMDELLTRA with AstraZeneca's IMFINZI reduced death risk by 58% in extensive stage small cell lung cancer. Median progression-free survival was 7.4 months vs. 1.9 months. Safety profiles were consistent with known data. Additional data reinforced sustained outcomes. The trial included 563 patients and was sponsored by Amgen with partial funding from AstraZeneca.

AstraZeneca reported that a combination of durvalumab and Amgen's tarlatamab-dlle reduced the risk of death by 58% compared to durvalumab alone in a phase III trial for extensive-stage small cell lung cancer (ES-SCLC). The median overall survival was 21.1 months for the combination therapy versus 12.7 months for durvalumab alone.